Indian Manufacture of New Generic Antiretrovirals: Implications for Global Access to Anti-Hiv Drugs

Venkatesh, Kartik K.; Kumarasamy, Nagalingeswaran; Mayer, Kenneth H.

doi:10.2217/hiv.09.55

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highest cost component of providing treatment for a country remains direct drug costs paid to the manufacturer. Hence, further constructive negotiations between international organizations, governments and pharmaceutical companies are crucial towards reaching the goal of expanded access to HAART [100]. Funding the future of sustainable HAART will require a shared multifaceted approach involving a combination of government revenue, private sector programs, international development assistance and contributions from other private foundations.…”

Section: Conclusion: Public Health Impact Of Haart For Preventionmentioning

confidence: 99%

How HIV Treatment Could Result in Effective Prevention

Venkatesh

Lurie

Mayer³

2010

Future Virol.

Self Cite

View full text Add to dashboard Cite

As the number of HIV infections continues to surpass treatment capacity, new HIV prevention strategies are imperative. Beyond individual clinical benefits, by rendering an individual less infectious, expanding access to highly active antiretroviral therapy (HAART) could also have a larger public health impact of curbing new HIV infections. Recent guidelines have moved towards initiating HAART at higher CD4 cell counts, thus increasing the number of individuals in need of treatment. A new treatment strategy is wanting that can simultaneously curb the epidemic and provide necessary treatment to those most in need. A recent debate has centered on whether an expansion of free and universal treatment, regardless of CD4 cell count, could be a means of HIV prevention. In light of the growing access to HAART in resource-limited settings and increasing evidence suggesting the clinical and prevention benefits of initiating treatment at higher CD4 cell counts, it is conceivable that, in the future, HAART will be an integral part of both individual-level clinical treatment programs as well as public health-based HIV prevention interventions.

show abstract

Section: Conclusion: Public Health Impact Of Haart For Preventionmentioning

confidence: 99%

How HIV Treatment Could Result in Effective Prevention

Venkatesh

Lurie

Mayer³

2010

Future Virol.

Self Cite

View full text Add to dashboard Cite

show abstract

HIV-1 Is Associated With Lower Group BStreptococcusCapsular and Surface-Protein IgG Antibody Levels and Reduced Transplacental Antibody Transfer in Pregnant Women

et al. 2015

View full text Add to dashboard Cite

show abstract

Low-Cost Generic Drugs Under The President’s Emergency Plan For AIDS Relief Drove Down Treatment Cost; More Are Needed

2012

View full text Add to dashboard Cite

The President's Emergency Plan for AIDS Relief (PEPFAR) was originally authorized in 2003 with the goal of supporting HIV prevention, treatment, and care within fifteen focus countries in the developing world. By September 2011 nearly 13 million people around the world were receiving HIV/AIDS-related care through PEPFAR, and 3.9 million were receiving antiretroviral treatment. However, in the early years of the program, access to antiretroviral drugs was hampered by the lack of a licensing process that the US government recognized for generic versions of these medications. Ultimately, the obstacle to approval of generic antiretroviral drugs was removed, which led to PEPFAR's considerable success at making these treatments widely available. This article outlines PEPFAR's evolving use of generic antiretroviral drugs to treat HIV in the developing world, highlights ongoing initiatives to increase access to generic antiretrovirals, and points to the need for mechanisms that will speed up the approval of new generic drugs. The striking decline in antiretroviral treatment costs, from $1,100 per person annually in 2004 to $335 per person annually in 2012, is due to the availability of effective generic antiretrovirals. Given growing resistance to existing drugs and the planned expansion of treatment to millions more people, access to newer generations of generic antiretrovirals will have to be expedited.

show abstract

Indian Manufacture of New Generic Antiretrovirals: Implications for Global Access to Anti-Hiv Drugs

Cited by 3 publications

References 16 publications

How HIV Treatment Could Result in Effective Prevention

How HIV Treatment Could Result in Effective Prevention

HIV-1 Is Associated With Lower Group BStreptococcusCapsular and Surface-Protein IgG Antibody Levels and Reduced Transplacental Antibody Transfer in Pregnant Women

Low-Cost Generic Drugs Under The President’s Emergency Plan For AIDS Relief Drove Down Treatment Cost; More Are Needed

Contact Info

Product

Resources

About